Advertisement

Liver Cancers pp 123-138 | Cite as

Transarterial Embolization Therapies in Hepatocellular Carcinoma: Principles of Management

  • Tim CrossEmail author
  • Jonathan C. Evans
Chapter

Abstract

Hepatocellular carcinoma (HCC) is the sixth commonest cancer worldwide and the third commonest cause of cancer-related death. The most commonly used algorithm for the staging and treatment of patients with HCC is that of the Barcelona Clinic Liver Cancer (BCLC). Patients with BCLC stage B disease at the time of first treatment are considered to be; unresectable, untransplantable and unablatable. The treatment aim is to elicit an objective response (complete or partial) and in some cases downstage the tumour such that a curative option might be considered in the future, e.g., liver transplantation or ablation. TACE should not be given where there is complete portal vein occlusion due to the risk of significant liver ischaemia and subsequent liver decompensation and death. The overall fitness of the patient should be considered and in the main reserved for patients with Child-Pugh A cirrhosis and performance status 0.The use of tools such as HAP and ART may help identify patients unlikely to benefit from TACE. The role of the best embolic agent or the use of drug-eluting beads remains controversial and should be determined by local availability and expertise and assessment of the patient. The best strategy for first treatment nonresponders, i.e., further TACE versus alternative therapy, has yet to be evaluated and should be studied in further trials. This chapter discusses the rationale for the use of TACE.

References

  1. 1.
    European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRefGoogle Scholar
  2. 2.
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73 e1.CrossRefGoogle Scholar
  3. 3.
    Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–9.CrossRefGoogle Scholar
  4. 4.
    Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60(1):110–7.CrossRefGoogle Scholar
  5. 5.
    Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–7.CrossRefGoogle Scholar
  6. 6.
    El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.CrossRefGoogle Scholar
  7. 7.
    Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29(3):285–92.CrossRefGoogle Scholar
  8. 8.
    Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38.CrossRefGoogle Scholar
  9. 9.
    Cross TJ, Villaneuva A, Shetty S, Wilkes E, Reeves H, et al. A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma. Frontline Gastroenterol. 2016;7:82–9.CrossRefGoogle Scholar
  10. 10.
    Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.CrossRefGoogle Scholar
  11. 11.
    Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24(10):2565–70.CrossRefGoogle Scholar
  12. 12.
    Solomon B, Soulen MC, Baum RA, Haskal ZJ, Shlansky-Goldberg RD, Cope C. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol. 1999;10(6):793–8.CrossRefGoogle Scholar
  13. 13.
    Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71.CrossRefGoogle Scholar
  14. 14.
    Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30(1):6–25. ReviewCrossRefGoogle Scholar
  15. 15.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42. ReviewCrossRefGoogle Scholar
  16. 16.
    Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.CrossRefGoogle Scholar
  17. 17.
    Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–64.CrossRefGoogle Scholar
  18. 18.
    Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48(6):571–7.CrossRefGoogle Scholar
  19. 19.
    Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, et al. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transpl. 2014;20(5):536–43.CrossRefGoogle Scholar
  20. 20.
    Massarweh NN, Davila JA, El-Serag HB, Duan Z, Temple S, et al. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. J Surg Res. 2016;200(2):552–9.CrossRefGoogle Scholar
  21. 21.
    Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34(17):2046–53.CrossRefGoogle Scholar
  22. 22.
    Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolization for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;Issue 3:Art. No CD004787.Google Scholar
  23. 23.
    Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. PLoS One. 2017;12(9):e0184597.CrossRefGoogle Scholar
  24. 24.
    Blackburn H, West S. Management of postembolization syndrome following hepatic transarterial chemoembolization for primary or metastatic liver cancer. Cancer Nurs. 2016;39(5):E1–E18.CrossRefGoogle Scholar
  25. 25.
    Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.CrossRefGoogle Scholar
  26. 26.
    Hasan S, Thai N, Uemura T, Kudithipudi V, Renz P, et al. Hepatocellular carcinoma with child Pugh-a cirrhosis treated with stereotactic body radiotherapy. World J Gastrointest Surg. 2017;9(12):256–63.CrossRefGoogle Scholar
  27. 27.
    Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Muller C, et al. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol. 2014;60(1):118–26.CrossRefGoogle Scholar
  28. 28.
    Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(8):565–75.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of HepatologyThe Royal Liverpool HospitalLiverpoolUK
  2. 2.Department of RadiologyThe Royal Liverpool HospitalLiverpoolUK

Personalised recommendations